FAQ
Log In
Sunday 4th December 2016
News
 › 
 › 

New breast cancer drug

2nd October 2012

A new type of breast cancer medication which combines the drug Herceptin with a chemotherapy drug could extend the lives of women with HER-2 positive breast cancer by six months.

The drug T-DM1, which is made by Roche, can destroy cancer cells without causing too much damage to healthy cells. Paul Ellis, professor of cancer medicine at King’s College London, said: "HER-2 positive breast cancer is very aggressive and once it progresses to the “advanced” stage it becomes very difficult to treat. These results are truly outstanding and will positively alter the outlook and outcomes for patients."

 

Share this page

Comments

There are no comments for this article, be the first to comment!


Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016